EMA Authorised: Livtencity (Maribavir) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

EU authorised Livtencity (maribavir) for cytomegalovirus infections, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• LIVTENCITY (MARIBAVIR)

Snippet

Status: Authorised. Therapeutic area: Cytomegalovirus Infections. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 15/05/2025. Orphan medicine